Results 201 to 210 of about 2,475,393 (270)

Glucagon-Like Peptide-1 Receptor Agonists and Risk of Mental Health Disorders in Type 2 Diabetes: Active Comparator, New User Cohort Study. [PDF]

Diabetes Obes Metab
Kim C, Kim S, Lee DY, Han E, Lee YH, You SC.   +5 more
europepmc   +1 more source

Durability and Safety of Imeglimin as an Add-On to DPP-4 Inhibitors in Japanese Type 2 Diabetes: The 104-Week FAMILIAR Trial. [PDF]

Diabetes Obes Metab
Shimoda M, Osonoi T, Iwamoto M, Kaneto H, Kaku K.   +4 more
europepmc   +1 more source

Dipeptidyl peptidase-4 inhibitors and cardiovascular and renal disease in type 2 diabetes: What have we learned from the CARMELINA trial? [PDF]

Diabetes and Vascular Disease Research, 2019
Dipeptidyl peptidase-4 inhibitors are a relatively new class of oral anti-hyperglycaemic drugs to treat type 2 diabetes through prevention of degradation of incretins by the dipeptidyl peptidase-4 enzyme.
Nordin Mj Hanssen
exaly   +2 more sources

Some of the next articles are maybe not open access.

Related searches:

A potent dipeptide inhibitor of dipeptidyl peptidase IV

Bioorganic & Medicinal Chemistry Letters, 1998
A series of novel potent inhibitors of dipeptidyl peptidase IV (DPP-IV) has been developed. A brief structure-activity relationship of the inhibitors was investigated. The dipeptide TSL-225, tryptophyl-1,2,3,4-tetrahydroisoquinoline-3-carboxylic acid, was identified with the critical structure for the inhibitory activity.
M, Yamada, C, Okagaki, T, Higashijima, S, Tanaka, T, Ohnuki, T, Sugita   +5 more
openaire   +2 more sources

Suppression of arthritis by the inhibitors of dipeptidyl peptidase IV

International Journal of Immunopharmacology, 1997
Dipeptidyl peptidase IV (DP IV, CD26) is a serine exoprotease which selectively cleaves the penultimate proline residue of polypeptides. This enzyme is also expressed as a surface marker on activated T cells. In order to assess the relevance of DP IV in immunological disorders, we evaluated the in vivo effects of specific DP IV inhibitors using two ...
S, Tanaka, T, Murakami, H, Horikawa, M, Sugiura, K, Kawashima, T, Sugita   +5 more
openaire   +2 more sources

Recent patents of dipeptidyl peptidase IV inhibitors

Expert Opinion on Therapeutic Patents, 2011
The serine exopeptidase DPP IV is a dual protein able to work as an enzyme and an interacting protein. The incretin molecules glucagon-like peptide 1 (GLP-1) and glucose-dependent insulinotropic peptide (GIP) are hydrolyzed by DPP IV into inactive forms, which are unable to promote insulin secretion.
Laura, Mendieta, Teresa, Tarrago, Ernest, Giralt   +2 more
openaire   +2 more sources

Fluoropyrrolidine amides as dipeptidyl peptidase IV inhibitors

Bioorganic & Medicinal Chemistry Letters, 2004
Amides derived from fluorinated pyrrolidines and 4-substituted cyclohexylglycine analogues have been prepared and evaluated as inhibitors of dipeptidyl dipeptidase IV (DP-IV). Analogues which incorporated (S)-3-fluoropyrrolidine showed good selectivity for DP-IV over quiescent cell proline dipeptidase (QPP).
Charles G, Caldwell, Ping, Chen, Jiafang, He, Emma R, Parmee, Barbara, Leiting, Frank, Marsilio, Reshma A, Patel, Joseph K, Wu, George J, Eiermann, Aleksandr, Petrov, Huaibing, He, Kathryn A, Lyons, Nancy A, Thornberry, Ann E, Weber   +13 more
openaire   +2 more sources

Dipeptide Phosphonates as Inhibitors of Dipeptidyl Peptidase IV

Journal of Medicinal Chemistry, 1994
A series of dipeptides which contained phosphonate analogs of proline and piperidine-2-carboxylic acid (homoproline) have been synthesized and tested as inhibitors of DPP-IV. The rates of inhibition of DPP-IV by these compounds are moderate, but the inhibitors are quite specific. The best inhibitor in the series is Ala-PipP(OPh-4-Cl)2 (13), which has a
B, Boduszek, J, Oleksyszyn, C M, Kam, J, Selzler, R E, Smith, J C, Powers   +5 more
openaire   +2 more sources